Adaptive deep brain stimulation for Parkinson's disease demonstrates reduced speech side effects compared to conventional stimulation in the acute setting.

Adaptive deep brain stimulation for Parkinson's disease demonstrates reduced speech side effects compared to conventional stimulation in the acute setting.

Little S, Tripoliti E, Beudel M, Pogosyan A, Cagnan H, Herz DM, Bestmann S, Aziz T, Cheeran B, Zrinzo L, Hariz M, Hyam J, Limousin P, Foltynie T, Brown P
We have shown that ‘deep brain stimulation’ for the treatment of Parkinson’s disease can be made more efficient if it is triggered by abnormal brain signals. Here, we show that the speech impairments that can follow the stimulation procedure can be reduced when such triggering is introduced, without reducing the overall effectiveness of the treatment for relieving other movement difficulties.
Scientific Abstract:
Objective: Adaptive deep brain stimulation (aDBS) appears at least as effective in treating motor impairment as conventional stimulation (cDBS) in Parkinson’s disease. Here we investigate whether aDBS can also increase the therapeutic window of stimulation and thereby decrease speech side-effects compared to conventional stimulation (cDBS) in Parkinson’s disease. Methods: We tested 8 subjects 3-6 days after surgery using a blinded standardised speech intelligibility test (SIT) under aDBS, cDBS and off stimulation conditions in the acute setting. Motor scores were also assessed in 6 of the 8 subjects using blinded video recordings. Results: With electrical parameters of stimulation optimised to aDBS, speech intelligibility was significantly better (SIT score 70.4 ± 6.4 %) compared to parameter-matched cDBS (60.5 ± 8.2 %, p=0.02) with motor function also enhanced (p=0.04). Interpretation: At equal stimulation parameters, acute aDBS does not compromise speech intelligibility whilst being superior to cDBS for motor efficacy in the acute setting.
Publication Year: 
2016
Citation:
2016. J. Neurol. Neurosurg. Psychiatr., 87(12): 1388-1389.
Free Full Text at Europe PMC: